TABLE III.
Treatment-emergent adverse events occurring in ten or more patients
| Event | Patient group [n (%)] | ||
|---|---|---|---|
|
| |||
| CLL (n=16) | iNHL (n=74) | Overall (n=90) | |
| Any event | 16 (100.0) | 74 (100.0) | 90 (100.0) |
| Nausea | 12 (75.0) | 51 (68.9) | 63 (70.0) |
| Fatigue | 8 (50.0) | 43 (58.1) | 51 (56.7) |
| Vomiting | 9 (56.3) | 27 (36.5) | 36 (40.0) |
| Diarrhea | 9 (56.3) | 21 (28.4) | 30 (33.3) |
| Neutropenia | 5 (31.3) | 24 (32.4) | 29 (32.2) |
| Constipation | 5 (31.3) | 23 (31.1) | 28 (31.1) |
| Pyrexia | 6 (37.5) | 21 (28.4) | 27 (30.0) |
| Decreased appetite | 4 (25.0) | 20 (27.0) | 24 (26.7) |
| Headache | 5 (31.3) | 17 (23.0) | 22 (24.4) |
| Anemia | 4 (25.0) | 17 (23.0) | 21 (23.3) |
| Thrombocytopenia | 5 (31.3) | 14 (18.9) | 19 (21.1) |
| Dysgeusia | 0 | 17 (23.0) | 17 (18.9) |
| Cough | 3 (18.8) | 13 (17.6) | 16 (17.8) |
| Dyspepsia | 1 (6.3) | 15 (20.3) | 16 (17.8) |
| Dizziness | 2 (12.5) | 13 (17.6) | 15 (16.7) |
| Chills | 3 (18.8) | 11 (14.9) | 14 (15.6) |
| Edema peripheral | 2 (12.5) | 12 (16.2) | 14 (15.6) |
| Decreased platelet count | 2 (12.5) | 11 (14.9) | 13 (14.4) |
| Dry mouth | 2 (12.5) | 10 (13.5) | 12 (13.3) |
| Dyspnea | 3 (18.8) | 9 (12.2) | 12 (13.3) |
| Decreased neutrophil count | 4 (25.0) | 7 (9.5) | 11 (12.2) |
| Decreased weight | 2 (12.5) | 9 (12.2) | 11 (12.2) |
| Oropharyngeal pain | 2 (12.5) | 8 (10.8) | 10 (11.1) |
| Rash | 2 (12.5) | 8 (10.8) | 10 (11.1) |
CLL = chronic lymphocytic leukemia; iNHL = indolent non-Hodgkin lymphoma.